MRK•benzinga•
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
Summary
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga